Responses

PDF
Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Re:Data inconclusive to recommend oral azithromycin over oral doxycycline in meibomian gland dysfunction

    We would like to thank Michel J. Belliveau for the comments on our recently published trial(1) on comparing the oral Azithromycin with doxycycline. All the concerns regarding the data presentation are being addressed in the following paragraphs. The null hypothesis had been written in the study design (ClinicalTrials.gov; NCT01783860) which was not mentioned in the article because of word number limitation. It was a tw...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Data inconclusive to recommend oral azithromycin over oral doxycycline in meibomian gland dysfunction

    Kashkouli and colleagues (1) have studied a subject with high clinical relevance. Meibomian gland dysfunction is prevalent and treatment often unsatisfactory. Oral azithromycin has advantages over oral doxycycline including dosing and side effects as reviewed in the article.

    There are a few problems with the methods to be highlighted so that readers can draw accurate conclusions, and validation studies be constr...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    An additional explanation for azithromycin's efficacy in treating meibomian gland dysfunction
    • Yang Liu
    • Other Contributors:
      • Juan Ding, David A. Sullivan

    We would like to congratulate Dr. Kashkouli et al for their recently published paper "Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomized double masked open label clinical trial". The authors found that azithromycin induced a significantly better overall clinical response than doxycycline, and attributed this effect to the antibacterial and anti-inflammatory effects of azithromycin. However,...

    Show More
    Conflict of Interest:
    None declared.